Moderna Discontinues mRNA Vaccine for Congenital CMV
Moderna has announced the results of a Phase 3 trial evaluating the efficacy of mRNA-1647, its investigational cytomegalovirus (CMV) vaccine.
The study did not meet its primary endpoint of preventing CMV infection in seronegative female participants of childbearing age (16-40 years).
"The announcement is disappointing for families and healthcare professionals who have been eagerly awaiting a CMV vaccine to prevent congenital CMV, a leading infectious cause of birth defects," said Stéphane Bancel, Chief Executive Officer of Moderna.
As a result, Moderna will discontinue its congenital CMV clinical development program.
Author's summary: Moderna stops CMV vaccine development due trial failure.
More News
- Furusato takes maiden Moto3 victory at Sepang
- Advisors Are Piling Into the RIA Channel. That May Not Be a Good Thing
- Daniel Mesfin and Eebbissee Addunyaa crowned Dublin Marathon winners | BreakingNews
- MotoGP: Alex Marquez clinches Sepang victory as Bagnaia suffers late DNF
- Somber Start, Triumphant Finish: Furusato Claims Maiden Victory Amid Difficult Day in Sepang